Hottub News

Merck and Daiichi Sankyo withdraw FDA approval application for new lung cancer drug 'Ifinatamab Deruxtecan'

머크·다이이찌산쿄, 폐암 신약 'Ifinatamab Deruxtecan' FDA 허가 신청 철회

1 report from 1 outlet in 1 language · first reported · updated · JSON

HealthMerckDaiichi Sankyoifinatamab deruxtecan

Reports

  1. 머크·다이이찌산쿄, 폐암 신약 'Ifinatamab Deruxtecan' FDA 허가 신청 철회Merck and Daiichi Sankyo withdraw FDA approval application for new lung cancer drug 'Ifinatamab Deruxtecan'cdn.pharmnews.com · ko ·

More in Health

  1. Democratic Republic of Congo: More than 4,000 people in the DR Congo have died from Ebola97 outlets
  2. Former Eljamel patient’s ‘shock’ at health board’s approach to inquiry131 outlets
  3. More than 4000 Ebola deaths in Democratic Republic of Congo63 outlets
  4. Life expectancy almost back to pre-Covid levels, says WHO39 outlets
  5. Here's why experts say now is an ideal time to protect yourself from flu45 outlets
  6. Disease-carrying ticks 'living for longer' in UK31 outlets